Aardvark Therapeutics (NASDAQ:AARD) CEO Purchases $101,360.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee purchased 7,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $14.48 per share, for a total transaction of $101,360.00. Following the transaction, the chief executive officer directly owned 1,551,613 shares in the company, valued at approximately $22,467,356.24. This represents a 0.45% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tien-Li Lee also recently made the following trade(s):

• On Monday, September 15th, Tien-Li Lee acquired 10,000 shares of Aardvark Therapeutics stock. The stock was purchased at an average price of $9.66 per share, with a total value of $96,600.00.

Aardvark Therapeutics Price Performance

NASDAQ:AARD opened at $14.43 on Monday. Aardvark Therapeutics, Inc. has a 1-year low of $4.88 and a 1-year high of $19.58. The company has a 50-day moving average of $11.93 and a 200 day moving average of $11.73. The firm has a market cap of $314.14 million and a PE ratio of -6.81.

Aardvark Therapeutics (NASDAQ:AARD) last posted its earnings results on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.07.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AARD. Cormorant Asset Management LP acquired a new position in shares of Aardvark Therapeutics during the first quarter valued at about $6,009,000. Braidwell LP purchased a new stake in Aardvark Therapeutics during the 1st quarter worth approximately $3,755,000. Millennium Management LLC purchased a new stake in Aardvark Therapeutics during the 3rd quarter worth approximately $4,248,000. Adage Capital Partners GP L.L.C. acquired a new position in Aardvark Therapeutics during the 1st quarter valued at approximately $1,878,000. Finally, Cresset Asset Management LLC purchased a new position in shares of Aardvark Therapeutics in the third quarter worth $1,951,000.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on AARD shares. Cantor Fitzgerald restated an “overweight” rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. Stifel Nicolaus began coverage on Aardvark Therapeutics in a research report on Monday, September 29th. They set a “buy” rating and a $24.00 price objective on the stock. BTIG Research began coverage on shares of Aardvark Therapeutics in a report on Friday, November 7th. They issued a “buy” rating and a $26.00 target price for the company. Jones Trading began coverage on shares of Aardvark Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $33.00 price target for the company. Finally, William Blair assumed coverage on shares of Aardvark Therapeutics in a research report on Friday. They issued an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.44.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.